- Previous Close
0.0165 - Open
0.0185 - Bid 0.0230 x --
- Ask 0.0250 x --
- Day's Range
0.0170 - 0.0275 - 52 Week Range
0.0100 - 0.1784 - Volume
2,521,115 - Avg. Volume
875,561 - Market Cap (intraday)
9.376M - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1400 - Earnings Date Nov 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
www.cyxone.comRecent News: CYXO.ST
View MorePerformance Overview: CYXO.ST
Trailing total returns as of 11/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYXO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYXO.ST
View MoreValuation Measures
Market Cap
6.19M
Enterprise Value
374.45k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.21
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.00%
Return on Equity (ttm)
-68.53%
Revenue (ttm)
3.52M
Net Income Avi to Common (ttm)
-22.16M
Diluted EPS (ttm)
-0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
6.28M
Total Debt/Equity (mrq)
1.59%
Levered Free Cash Flow (ttm)
-16.74M